Merhaba,
Label
Türk Hematoloji Derneği
  •  Arama
  • İletişim

Highlights of Past EHA (HOPE) EMEA 2020

TSH Logo enEHA and the Turkish Society of Hematology are very happy to announce that the first virtual Highlights of Past EHA will take place on October 9 and 10, 2020. The program will bring a broad range of topics from the EHA25 Virtual Congress to the hematology community in Turkey, the Middle East, North Africa and the Balkan region. Registration will open soon for this exciting virtual program bringing the EHA congress updates to your own screen.

Registration page:

https://ehaweb.org/meetings/hope-emea-2020/registration/

About the program

The format of the program has been completely transformed and will be comprised of update presentations in the various fields of hematology, followed by break-out sessions with experts on specific topics. The new format will focus on the interaction between the speakers and the participants by creating space for questions and discussion. In addition, there will be key note lectures deepening your knowledge on specific topics.
The main topics of the program are as follows:

  • Acute myeloid leukemia
  • Myelodysplastic syndromes
  • Plasma cell disorders
  • Myeloproliferative neoplasms
  • Lymphoproliferative disorders
  • Benign hematology
  • Hemoglobinopathies
  • CAR-T cell therapy

Target audience

The main focus of this highlights program are (general) hematologists, clinicians, scientists or trainees, from Turkey and the Balkan countries, the Middle East, and North Africa.

Participants from other countries are also welcome, but dedicated HOPE Meetings are in preparation for Latin America and Asia, and the details can be found on the main meeting page here.

Sponsorship

Are you interested to support this interesting virtual program, then please don’t hesitate to contact sponsorship@ehaweb.org.

EBAH CME accreditation

This meeting is accredited by the European Board for Accreditation in Hematology (EBAH) CME. EBAH CME is the best way for hematologists to master the latest developments within the specialty of hematology. Staying abreast of these scientific developments and keeping in touch with the up-to-date views on clinical policy will enable you to raise your professional level, ultimately resulting in the best treatment for your patients.

 

 

14:00 - 14:15 Opening ceremony

14:15 - 15:30 Session 1: AML

14:15 - 14:45  Overview Presentation

  • Virtual Room A
    Update on AML
    K Döhner (Germany)

14:45 - 15:30 Parallel Expert break-out sessions

  • Virtual Room A
    To be defined based on overview lecture
    Speaker: to be announced
    Chair: G Ossenkoppele (The Netherlands)
  • Virtual Room B
    Down syndrome in AML
    S Izraeli (Israel)
    Chair: H Oren (Turkey)

  • Virtual Room C
    Treatment of pediatric AML
    GJ Kaspers (The Netherlands)
    Chair: V Hazar (Turkey)

15:30 - 15:45 A moment to stretch & relax

15:45 - 17:00 Session 2: MDS

15:45 - 16:15 Overview Presentation

  • Virtual Room A
    Update on MDS
    P Fenaux (France)
    Chair: İ Alacacıoğlu (Turkey)

16:15 - 17:00 Parallel Expert break-out sessions

  • Virtual Room A
    To be defined based on overview lecture
    P Fenaux (France)
    Chair: İ Alacacıoğlu (Turkey)
  • Virtual Room B
    Germline mutations and risk of bone marrow failure and MDS
    J Soulier (France)
    Chair: S Izraeli (Israel)
  • Virtual Room C
    Understanding the pathophysiology: Risk based treatment of MDS in 2020
    A Almeida (Portugal)
    Chair: AM Demir (Turkey)

17:00 - 17:15 A moment to stretch & relax

17:15 - 17:45 Satellite Symposium Janssen: A look into the future: How might we identify the most appropriate cellular therapy for patients with Multiple Myeloma?

17:45 - 19:00 Session 3: Plasma cell disorders

17:45 - 18:15 Overview Presentation

  • Virtual Room A
    Update on multiple myeloma
    Speaker: M Beksaç (Turkey)
    Chair: to be announced

18:15 - 19:00  Parallel Expert break-out sessions

  • Virtual Room A
    Risk assesment at diagnosis and risk based therapy
    Speaker: M Beksaç (Turkey)
    Chair: to be announced

  • Virtual Room B
    Diagnosis and current management of AL amyloidosis
    G Palladini (Italy)
    Chair: A Salihoğlu (Turkey)
  • Virtual Room C
    Diagnosis and treatment of high risk MM: Update 2020 (incl. immunotherapies)
    M Cavo (Italy)
    Chair: ÖG Sevindik (Turkey)

19:00 - 19:15  Close of Day 1

09:00 Opening day 2

09:00 - 09:30 Keynote Lecture 1

  • Virtual Room A
    CAR T cells in 2020
    A Urbano-Ispizua (Spain)
    Chair: J Gribben (United Kingdom)

09:30 – 10:45 Session 4: Myeloproliferative neoplasms

09:30 – 10:00  Overview Presentation

  • Virtual Room A
    Update on MPN
    A Almeida (Portugal)
    Chair: MC Ar (Turkey)

10:00 – 10:45 Parallel Expert break-out sessions

  • Virtual Room A
    To be defined based on overview lecture
    A Almeida (Portugal)
    Chair: MC Ar (Turkey)

  • Virtual Room B
    Current standards in the diagnosis and treatment of mastocytosis
    Speaker to be announced
    Chair: SA Yavuz (Turkey)
  • Virtual Room C
    Challenges in SCT in myelofibrosis
    E Ollavaria (United Kingdom)
    Chair: D Wolf (Austria)

10:45 - 11:00 A moment to stretch & relax

11:00 - 12:15 Session 5: Lymphoproliferative disorders

11:00 - 11:30  Overview Presentation

  • Virtual Room A
    Update on lymphoma
    G Gaidano (Italy)
    Chair: J Gribben (United Kingdom)

11:30 – 12:15 Parallel Expert break-out sessions

  • Virtual Room A
    To be defined based on overview lecture
    G Gaidano (Italy)
    J Gribben (United Kingdom)

  • Virtual Room B
    Molecular classification and treatment of aggressive B-cell lymphomas
    A Davies (United Kingdom)
    Chair: M Özcan (Turkey)
  • Virtual Room C
    Molecular classification and biomarker driven therapies in T-cell lymphomas
    R Koch (Germany)
    Chair to be announced

12:15 - 13:15 Time for Lunch!

12:45 - 13:15 Satellite Symposium Amgen: Blinatumomab in the treatment of acute lymphoblastic leukemia

13:15 - 13:45 Keynote Lecture 2

  • Virtual Room A
    CLL
    J Gribben (United Kingdom)
    Chair: GH Özsan (Turkey)

13:45 - 15:00 Session 6: Benign hematology

13:45 - 14:15 Overview Presentation

  • Virtual Room A
    Update on VTE
    R Kucukkaya (Turkey)
    Chair: MC Ar (Turkey)

14:15 - 15:00 Parallel Expert break-out sessions

  • Virtual Room A
    To be defined based on overview lecture
    R Kucukkaya (Turkey)
    Chair: MC Ar (Turkey)
  • Virtual Room B
    TTP versus HUS: Understanding the disease
    M Scully (United Kingdom)
    Chair: N Andıç (Turkey)
  • Virtual Room C
    Current understanding and management of DIC
    CH Toh (United Kingdom)
    Chai: S Eichinger (Austria)

15:00 - 15:15 A moment to stretch & relax

15:15 - 15:45 Satellite Symposium by Roche: Setting the new norm in the treatment of Follicular Lymphoma

15:45 - 16:30 EHA-TSH Joint Symposium

  • Virtual Room A
    Iron Overload and Monitoring in Hemoglobinopathies
    Ş Ünal Cangül (Turkey)
    Chair: GH Özsan (Turkey)
    Title to be announced
    MD Cappellini (Italy)
    J Gribben (United Kingdom)

16:30 Closing Remarks